stockrow
Saturday 7 November 2026
Export NNVC’s income statement to Excel — free account
NanoViricides, Inc.
NNVC Healthcare Biotechnology
- EPS
- +23.1%
- Free cash flow
- −23.9%
Quarter to June 2026, against a year earlier
1.33
0.04
+3.10%
Follow NNVC
Alert me
NanoViricides, Inc. (NNVC) P/E ratio
NanoViricides, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VERU Veru Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| INMB INmune Bio, Inc. compare | n/m |
| NNVC NanoViricides, Inc. | n/m |
| PMN Promis Neurosciences compare | n/m |
| EYPT EyePoint, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)